spacer
home > ebr > winter 2002 > realising the potential of human cells for therapy
PUBLICATIONS
European Biopharmaceutical Review

Realising the Potential of Human Cells for Therapy

Cell therapy offers the potential to revolutionise health care. Instead of taking medicines that address only the symptoms of chronic disease, cell implants and engineered tissues will be able to cure a broad range of health conditions. The potential returns, both in terms of clinical benefit and financial reward, are significant. Not only can cell therapies displace expensive medicines, they can also greatly reduce the costs of supporting patients on long-term medical regimes. This is not a theoretical proposition - cell and cell-derived therapies are already being used effectively for a variety of applications.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Will West, Product Development Director at CellFactors Dr Will West is Product Development Director at CellFactors plc, where his main focus has been on developing and commercialising SkeletexTM, a human cell-derived matrix that induces bone formation.
His scientific background is in immunology, virology and cell culture, and he completed his PhD, sponsored by Unilever (UniPath), in 1992. Following this, Dr West held a post-doctoral position at the National Institute of Biological Standards and Control, working on HIV vaccines and MHC proteins. Dr West subsequently worked at Procter & Gamble, responsible for product and claims development in a number of health care therapeutic areas. He has an MBA from London Business School.

spacer
Dr Will West
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

What You Need To Know About Thermal Shipping Technologies

Temptime Corporation

This paper presents highlights from a thermal performance study conducted by Modality Solutions LLC. The study examined the performance of five shipping technologies commonly used by specialty pharmacies to transport high-value refrigerated specialty medicines against an industry accepted temperature profile standard.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement